News ArticleMax Healthcare Announces Q2 FY2027 Results and ₹190 Crore Expansion for Noida and Vaishali Hospitals
Board approves revised ₹1,143 crore project cost for Gurugram hospital with April 2027 completion; appoints Dr. Dharmender Kumar as Director & Chief - Public Affairs
Max Healthcare Institute Limited announced its unaudited standalone and consolidated financial results for Q2 and H1 FY2027. The company also approved capital expenditures totaling approximately ₹190 crore for expanding its Max Super Speciality Hospitals in Noida and Vaishali, along with a revised ₹1,143 crore budget and April 2027 completion timeline for a new 525-bed hospital in Gurugram.
Max Healthcare Institute Limited
Financial Results
Max Healthcare Institute Limited approved its unaudited financial results for the quarter and half year ended September 30, 2026, and sanctioned ₹93 crore and ₹97 crore capital expenditure for upgrading hospitals at Noida and Vaishali, respectively. The company also revised the Gurugram hospital project's cost to ₹1,143 crore with a new completion timeline of April 2027.
The Board approved unaudited standalone and consolidated financial results for Q2 and H1 FY2027, endorsed by statutory auditors M/s. S.R. Batliboi & Co. LLP.
A capital expenditure of approximately ₹93 crore was approved for redevelopment and clinical capacity enhancement at Max Super Speciality Hospital, Sector-128, Noida, operated by the wholly owned subsidiary Crosslay Remedies Limited.
An additional ₹97 crore was approved for vertical expansion at Max Super Speciality Hospital, Vaishali, involving construction over the existing hospital tower, also managed by Crosslay.
The Gurugram hospital project at Sector-56, comprising around 525 beds, saw its cost revised upward to ₹1,143 crore due to enhanced specifications and fit-outs, with a completion target extended to April 2027.
Dr. Dharmender Kumar will join Max Healthcare as Director & Chief - Public Affairs from November 1, 2026, in a senior management role.
Highlights
- Unaudited Q2 & H1 FY2027 financial results approved by Max Healthcare Board.
- ₹93 crore allocated for Noida hospital redevelopment and capacity enhancement.
- ₹97 crore approved for additional floors at Vaishali hospital tower.
- Gurugram 525-bed hospital project cost revised to ₹1,143 crore, completion moved to April 2027.
- Appointment of Dr. Dharmender Kumar as Director & Chief - Public Affairs effective November 1, 2026.
Key Data Snapshot
What happened
- Max Healthcare approved its unaudited standalone and consolidated financial results for quarter and half year ended September 30, 2026.
- The Board sanctioned major capital expenditure for expanding Max Super Speciality Hospitals in Noida and Vaishali.
- The existing Gurugram hospital project’s budget was revised upward with an extended timeline for completion.
- A senior management appointment was made, adding Dr. Dharmender Kumar as Director & Chief - Public Affairs.
Key details
- Noida hospital expansion involves redevelopment and clinical capacity enhancement with a ₹93 crore budget.
- Vaishali hospital will be expanded by constructing additional floors over the existing tower with ₹97 crore approved.
- Gurugram hospital project cost increased primarily due to facade and interior enhancements, with target completion shifted to April 2027.
- Dr. Dharmender Kumar’s appointment takes effect November 1, 2026, following nomination committee recommendation.
Regulatory and governance context
- Financial results come with unmodified limited review reports from statutory auditors M/s. S.R. Batliboi & Co. LLP.
- All disclosures are compliant with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Board meeting started at 12:50 PM IST and concluded at 2:35 PM IST on October 30, 2026.
Highlights
- Unaudited Q2 & H1 FY2027 financial results approved by Max Healthcare Board.
- ₹93 crore allocated for Noida hospital redevelopment and capacity enhancement.
- ₹97 crore approved for additional floors at Vaishali hospital tower.
- Gurugram 525-bed hospital project cost revised to ₹1,143 crore, completion moved to April 2027.
- Appointment of Dr. Dharmender Kumar as Director & Chief - Public Affairs effective November 1, 2026.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Navin Fluorine International Ltd Reports ₹269.24 Crore Q2 Profit and Declares ₹8 Interim Dividend for FY2026-27
Navin Fluorine International Limited released its unaudited consolidated financial results for the quarter and half year ended September 30, 2026. The company recorded a profit after tax of ₹269.24 crore for the quarter and declared an interim dividend of ₹8 per equity share for the fiscal year 2026-27.
Read Full Story
GAIL India Reports ₹11,611.44 Crore Profit Before Tax for First Half of 2026
GAIL (India) Limited posted a profit before tax of ₹11,611.44 crore for the half year ended September 30, 2026, with total income of ₹86,116.52 crore, reflecting its continuing scale of operations. The company released its unaudited standalone financial results, which include ongoing legal matters contested with the Petroleum and Natural Gas Regulatory Board and central excise authorities.
Read Full Story
Sun Pharmaceutical Posts Rs 8,712.9 Million Profit in Q2 FY2026-27 with Revenue Rs 61,419.2 Million
Sun Pharmaceutical Industries Limited announced its unaudited standalone financial results for the quarter and half year ended 30 September 2026, posting a net profit of Rs 8,712.9 million for the quarter on total revenue of Rs 61,419.2 million from operations. The results include an exceptional item of Rs 315.3 million.
Read Full Story
